Skip to main content
OpenTrials
Completed

NCT Number: NCT00362934

Comparison of the Combination of Fenofibrate and Simvastatin Versus Atorvastatin

Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia. Statins and fibrates have complementary mechanisms and can be coadministered to patients with mixed hyperlipidemia. The overall objective of the study is to compare the efficacy and safety of combining fenofibrate and simvastatin versus atorvastatin monotherapy in patients with mixed hyperlipidemia at risk of cardiovascular diseases.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hyperlipidemia Dyslipidemias Hyperlipidemias Lipid Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Site 501, Haskovo, Bulgaria

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Mixed dyslipidemia.

Exclusion criteria

  • Known hypersensitivity to fenofibrates or simvastatin or atorvastatin
  • Pregnant or lactating women
  • Contra-indication to fenofibrate or simvastatin or atorvastatin
  • Unstable or severe cardiac disease

Treatment and study plan

fenofibrate / simvastatin

Drug

Combination of fenofibrate and simvastatin 20 mg and 40 mg

atorvastatin

Drug

Atorvastatin 10 mg and 20mg

Primary outcomes

  1. Percent change from baseline to 12 weeks of treatment in Triglycerides

    Time frame: 12 weeks

  2. Percent change from baseline to 12 weeks of treatment in HDL-C

    Time frame: 12 weeks

  3. Percent change from baseline to 12 weeks of treatment in LDL-C

    Time frame: 12 weeks

Secondary outcomes

  1. Percent change from baseline to 12 weeks of treatment in Triglycerides

    Time frame: 24 weeks

  2. Percent change from baseline to 12 weeks of treatment in HDL-C

    Time frame: 24 weeks

  3. Percent change from baseline to 12 weeks of treatment in LDL-C

    Time frame: 24 weeks

Sponsors and collaborators

Lead sponsor

Solvay Pharmaceuticals

Industry

Registry information

Official study title

A Multicenter, Double-Blind, Randomized, Forced-Titration Study to Compare the Efficacy and Safety of the Combination of 145 mg Fenofibrate and 20 or 40 mg Simvastatin With Atorvastatin Monotherapy in Patients With Mixed Dyslipidemia at Risk of Cardiovascular Disease Not Adequately Controlled by 10 mg Atorvastatin Alone

Important dates

Study start
2006
Primary completion
2008
Study completion
2008
First posted
Aug 15, 2006
Registry last updated
Jul 8, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.